US6150101A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods of identifying a composition that alters connective tissue growth factor expression
Assignee: University of South Florida St. Petersburg
•
Filing: 1998-04-02
•
Granted: 2000-11-21
•
Expires: 2018-04-02
Abstract
Abstract The present invention provides a novel polypeptide, Connective Tissue Growth Factor (CTGF), polynucleotides encoding CTGF, and including 5' and 3' untranslated nucleotides, antibodies reactive with CTGF and means for producing CTGF. Also provided are diagnostic and therapeutic methods for using CTGF, as well as an assay for identifying compositions which affect the expression of CTGF polynucleotide. The invention provides a novel TGF- beta responsive element upstream of the polynucleotide encoding CTGF structural gene.
Inventors
- 👤 Gary R. Grotendorst
- 👤 Douglass M. Bradham, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 20:15
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61K38/39; A61P; A61P11/00; A61P13/00; A61P13/12; A61P17/00; A61P17/02; A61P19/00; A61P19/04; A61P27/00; A61P27/02; A61P27/06; A61P35/00; A61P43/00; A61P9/00; A61P9/10; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N5/0652; C12N5/0655
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
126 words
A method for identifying a composition which affects TGF-β induced connective tissue growth factor (CTGF) expression, the method comprising: (a) incubating components comprising the composition, TGF-β, and a nucleic acid molecule comprising an expressible nucleotide sequence operably linked to a TGF-β regulatory element (TβRE), said TβRE comprising the nucleotide sequence 5'-GTGTCAAGGGGTC-3' (SEQ ID NO: 8), wherein the incubating is carried out under conditions and for a time sufficient to allow the components to interact; and (b) comparing expression of the expressible nucleotide sequence operably linked to the TβRE in the presence of the composition with the level of expression of the nucleotide sequence in the absence of the composition, wherein a difference in the levels of expression identifies a composition that affects TGF-β induced CTGF expression.
Claim 2
Independent Claim
126 words
A method for identifying a composition which affects TGF-β induced connective tissue growth factor (CTGF) expression, the method comprising: (a) incubating components comprising the composition, TGF-β, and a nucleic acid molecule comprising an expressible nucleotide sequence operably linked to a TGF-β regulatory element (TβRE), said TβRE comprising the nucleotide sequence 5'-GTGTCAAGGGGTC-3' (SEQ ID NO: 8), wherein the incubating is carried out under conditions and for a time sufficient to allow the components to interact; and (b) comparing expression of the expressible nucleotide sequence operably linked to the TβRE in the presence of the composition with the level of expression of the nucleotide sequence in the absence of the composition, wherein a difference in the levels of expression identifies a composition that affects TGF-β induced CTGF expression.
Claim 3
Dependent Claim
11 words
The method of claim 1, wherein the composition inhibits CTGF expression.
Claim 4
Dependent Claim
11 words
The method of claim 1, wherein the composition stimulates CTGF expression.
Claim 5
Dependent Claim
43 words
The method of claim 1, wherein the expressible nucleotide sequence is selected from the group consisting of β-lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo, G418), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), β-galactosidase (β-gal), and xanthine guanine phosphoribosyltransferse (XGPRT).
Claim 6
Dependent Claim
21 words
The method of claim 1, wherein said TβRE comprises nucleotides 664 to 698 as set forth in SEQ ID NO: 1.
Claim 7
Dependent Claim
21 words
The method of claim 1, wherein said TβRE comprises nucleotides 1 to 897 as set forth in SEQ ID NO: 1.
Claim 8
Independent Claim
125 words
A method of identifying a composition that regulates connective tissue growth factor (CTGF) expression from a TGF-β regulatory element (TβRE), the method comprising: (a) incubating a nucleic acid molecule comprising a TβRE comprising the nucleotide sequence 5'-GTGTCAAGGGGTC-3' (SEQ ID NO: 8) operably linked to an expressible nucleotide sequence, and a composition suspected of having the ability to regulate expression of the expressible nucleotide sequence from the TβRE, under conditions and for a time sufficient to allow such expression; and (b) comparing the level of expression of the expressible nucleotide sequence in the presence of the composition with the level of expression in the absence of the composition, wherein a difference in the level of expression identifies a composition that regulates CTGF expression from the TβRE.
Claim 9
Independent Claim
125 words
A method of identifying a composition that regulates connective tissue growth factor (CTGF) expression from a TGF-β regulatory element (TβRE), the method comprising: (a) incubating a nucleic acid molecule comprising a TβRE comprising the nucleotide sequence 5'-GTGTCAAGGGGTC-3' (SEQ ID NO: 8) operably linked to an expressible nucleotide sequence, and a composition suspected of having the ability to regulate expression of the expressible nucleotide sequence from the TβRE, under conditions and for a time sufficient to allow such expression; and (b) comparing the level of expression of the expressible nucleotide sequence in the presence of the composition with the level of expression in the absence of the composition, wherein a difference in the level of expression identifies a composition that regulates CTGF expression from the TβRE.
Claim 10
Dependent Claim
21 words
The method of claim 7, wherein said TβRE comprises nucleotides 664 to 698 as set forth in SEQ ID NO: 1.
Claim 11
Dependent Claim
21 words
The method of claim 7, wherein said TβRE comprises nucleotides 1 to 897 as set forth in SEQ ID NO: 1.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-11-21 | 2004-05-22 | 2004-11-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-11-21 | 2008-05-22 | 2008-11-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-11-21 | 2012-05-22 | 2012-11-21 | $7700.00 | Window Closed / Lapsed |